Literature DB >> 17959665

Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections.

Elena Domingo-Gil1, Eva Pérez-Jiménez, Iván Ventoso, José L Nájera, Mariano Esteban.   

Abstract

The E3L gene of vaccinia virus (VACV) encodes the E3 protein that in cultured cells inhibits the activation of interferon (IFN)-induced proteins, double-stranded RNA-dependent protein kinase (PKR), 2'-5'-oligoadenylate synthetase/RNase L (2-5A system) and adenosine deaminase (ADAR-1), thus helping the virus to evade host responses. Here, we have characterized the in vivo E3 functions in a murine inducible cell culture system (E3L-TetOFF) and in transgenic mice (TgE3L). Inducible E3 expression in cultured cells conferred on cells resistance to the antiviral action of IFN against different viruses, while expression of the E3L gene in TgE3L mice triggered enhanced sensitivity of the animals to pathogens. Virus infection monitored in TgE3L mice by different inoculation routes (intraperitoneal and tail scarification) showed that transgenic mice became more susceptible to VACV infection than control mice. TgE3L mice were also more susceptible to Leishmania major infection, leading to an increase in parasitemia compared to control mice. The enhanced sensitivity of TgE3L mice to VACV and L. major infections occurred together with alterations in the host immune system, as revealed by decreased T-cell responses to viral antigens in the spleen and lymph nodes and by differences in the levels of specific innate cell populations. These results demonstrate that expression of the E3L gene in transgenic mice partly reverses the resistance of the host to viral and parasitic infections and that these effects are associated with immune alterations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17959665      PMCID: PMC2224365          DOI: 10.1128/JVI.01384-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Host-range restriction of vaccinia virus E3L-specific deletion mutants.

Authors:  E Beattie; E B Kauffman; H Martinez; M E Perkus; B L Jacobs; E Paoletti; J Tartaglia
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

2.  Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice.

Authors:  P A Buffet; A Sulahian; Y J Garin; N Nassar; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

3.  Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene.

Authors:  H Yuwen; J H Cox; J W Yewdell; J R Bennink; B Moss
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

4.  The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis.

Authors:  C Risco; J R Rodríguez; W Demkowicz; R Heljasvaara; J L Carrascosa; M Esteban; D Rodríguez
Journal:  Virology       Date:  1999-12-20       Impact factor: 3.616

5.  A locus control region at -12 kb of the tyrosinase gene.

Authors:  L Montoliu; T Umland; G Schütz
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

6.  Mechanism of interferon action: evidence for intermolecular autophosphorylation and autoactivation of the interferon-induced, RNA-dependent protein kinase PKR.

Authors:  D C Thomis; C E Samuel
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms.

Authors:  M V Davies; H W Chang; B L Jacobs; R J Kaufman
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  Rescue of vaccinia virus lacking the E3L gene by mutants of E3L.

Authors:  H W Chang; L H Uribe; B L Jacobs
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Quantification of antigen specific CD8+ T cells using an ELISPOT assay.

Authors:  Y Miyahira; K Murata; D Rodriguez; J R Rodriguez; M Esteban; M M Rodrigues; F Zavala
Journal:  J Immunol Methods       Date:  1995-04-12       Impact factor: 2.303

10.  Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene.

Authors:  E Beattie; K L Denzler; J Tartaglia; M E Perkus; E Paoletti; B L Jacobs
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  6 in total

1.  Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins.

Authors:  José González-Santamaría; Michela Campagna; María Angel García; Laura Marcos-Villar; Dolores González; Pedro Gallego; Fernando Lopitz-Otsoa; Susana Guerra; Manuel S Rodríguez; Mariano Esteban; Carmen Rivas
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Translation control by protein kinase R restricts minute virus of mice infection: role in parvovirus oncolysis.

Authors:  Iván Ventoso; Juan J Berlanga; José M Almendral
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways.

Authors:  Chad Myskiw; Janilyn Arsenio; Rebekah van Bruggen; Yvon Deschambault; Jingxin Cao
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

4.  Inhibition of interferon gene activation by death-effector domain-containing proteins from the molluscum contagiosum virus.

Authors:  Crystal M H Randall; Sunetra Biswas; Catherine V Selen; Joanna L Shisler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-30       Impact factor: 11.205

5.  Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergence.

Authors:  Elena Domingo-Gil; René Toribio; José Luis Nájera; Mariano Esteban; Iván Ventoso
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

Review 6.  Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.

Authors:  Onur Kaynarcalidan; Sara Moreno Mascaraque; Ingo Drexler
Journal:  Biomedicines       Date:  2021-11-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.